Simon C Ling1, Wen Ye2, Daniel H Leung3, Oscar M Navarro4, Alexander Weymann5, Wikrom Karnsakul6, A Jay Freeman7, John C Magee8, Michael R Narkewicz9. 1. The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada. 2. University of Michigan, Ann Arbor, MI. 3. Baylor College of Medicine, Texas Children's Hospital, Houston, TX. 4. Department of Diagnostic Imaging, The Hospital for Sick Children and Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada. 5. Washington University School of Medicine, St Louis, MO. 6. Johns Hopkins University School of Medicine, Baltimore, MD. 7. Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA. 8. University of Michigan Medical School, Ann Arbor, MI. 9. Digestive Health Institute, Children's Hospital Colorado & University of Colorado School of Medicine, Aurora, CO.
Abstract
OBJECTIVES: Early identification of children with cystic fibrosis (CF) at risk for severe liver disease (CFLD) would enable targeted study of preventative therapies. There is no gold standard test for CFLD. Ultrasonography (US) is used to identify CFLD, but with concerns for its diagnostic accuracy. We aim to determine if differences in standard blood tests, imaging variables and noninvasive liver fibrosis indices correlate with liver US patterns, and thus provide supportive evidence that a heterogeneous US liver pattern reflects clinically relevant liver disease. METHODS: We studied baseline research abdominal US and bloodwork from 244 children with pancreatic insufficient CF, ages 3 to 12 years, enrolled in a prospective study of the ability of US to predict CF cirrhosis (PUSH study). Children with a heterogeneous (HTG) liver pattern on US (n = 62) were matched 1 : 2 in design with children with normal US (NL, n = 122). Analyses included children with nodular (NOD, n = 22) and homogeneous hyperechoic (HMG, n = 38) livers. RESULTS: Univariate analysis showed significant differences between US groups for standard blood tests, spleen size, and noninvasive liver fibrosis indices. Multivariable models discriminated NOD versus NL with excellent accuracy (AUROC 0.96). Models also distinguish HTG versus NL (AUROC 0.76), NOD versus HTG (0.78), and HMG versus NL (0.79). CONCLUSIONS: Liver US patterns in children with CF correlate with platelet count, spleen size and indices of liver fibrosis. Multivariable models of these biomarkers have excellent discriminating ability for NL versus NOD, and good ability to distinguish other US patterns, suggesting that US patterns correlate with clinically relevant liver disease.
OBJECTIVES: Early identification of children with cystic fibrosis (CF) at risk for severe liver disease (CFLD) would enable targeted study of preventative therapies. There is no gold standard test for CFLD. Ultrasonography (US) is used to identify CFLD, but with concerns for its diagnostic accuracy. We aim to determine if differences in standard blood tests, imaging variables and noninvasive liver fibrosis indices correlate with liver US patterns, and thus provide supportive evidence that a heterogeneous US liver pattern reflects clinically relevant liver disease. METHODS: We studied baseline research abdominal US and bloodwork from 244 children with pancreatic insufficient CF, ages 3 to 12 years, enrolled in a prospective study of the ability of US to predict CF cirrhosis (PUSH study). Children with a heterogeneous (HTG) liver pattern on US (n = 62) were matched 1 : 2 in design with children with normal US (NL, n = 122). Analyses included children with nodular (NOD, n = 22) and homogeneous hyperechoic (HMG, n = 38) livers. RESULTS: Univariate analysis showed significant differences between US groups for standard blood tests, spleen size, and noninvasive liver fibrosis indices. Multivariable models discriminated NOD versus NL with excellent accuracy (AUROC 0.96). Models also distinguish HTG versus NL (AUROC 0.76), NOD versus HTG (0.78), and HMG versus NL (0.79). CONCLUSIONS: Liver US patterns in children with CF correlate with platelet count, spleen size and indices of liver fibrosis. Multivariable models of these biomarkers have excellent discriminating ability for NL versus NOD, and good ability to distinguish other US patterns, suggesting that US patterns correlate with clinically relevant liver disease.
Authors: K Haag; M Rössle; A Ochs; M Huber; V Siegerstetter; M Olschewski; E Berger; S Lu; H E Blum Journal: AJR Am J Roentgenol Date: 1999-03 Impact factor: 3.959
Authors: Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson Journal: Hepatology Date: 2006-06 Impact factor: 17.425
Authors: Christopher H Goss; Nicole Mayer-Hamblett; Richard A Kronmal; Judy Williams; Bonnie W Ramsey Journal: J Cyst Fibros Date: 2006-07-07 Impact factor: 5.482
Authors: H Patriquin; C Lenaerts; L Smith; G Perreault; A Grignon; D Filiatrault; J Boisvert; C C Roy; A Rasquin-Weber Journal: Radiology Date: 1999-04 Impact factor: 11.105
Authors: Catherine Lenaerts; Chantale Lapierre; Heidi Patriquin; Nathalie Bureau; Guy Lepage; François Harel; Jacques Marcotte; Claude C Roy Journal: J Pediatr Date: 2003-09 Impact factor: 4.406
Authors: Steven Levitte; Lori W Lee; Jared Isaacson; Evan J Zucker; Carlos Milla; Richard A Barth; Zachary M Sellers Journal: Pediatr Radiol Date: 2021-03-24
Authors: Wen Ye; Daniel H Leung; Jean P Molleston; Simon C Ling; Karen F Murray; Jennifer L Nicholas; Suiyuan Huang; Boaz W Karmazyn; Roger K Harned; Prakash Masand; Adina L Alazraki; Oscar M Navarro; Randolph K Otto; Joseph J Palermo; Alexander J Towbin; Estella M Alonso; Wikrom W Karnsakul; Sarah Jane Schwarzenberg; Glenn F Seidel; Marilyn Siegel; John C Magee; Michael R Narkewicz; A Jay Freeman Journal: Hepatol Commun Date: 2021-05-13